Quality of Life and Toxicity of Stereotactic Radiotherapy in Pancreatic Tumors: A Case Series

REFERENCES

• National Comprehensive Cancer Network (NCCN). Pancreatic Adenocarcinoma. Practice Guidelines in Oncology. V. 2008. Fort Washington, PA: NCCN. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer Invest 2003;21(6):887–896.
   PubMed Web of Science ®Google Scholar
• Ceha HM, van Tienhoven G, Gouma DJ, Veenhof CH, Schneider CJ, Rauws EA, Phoa SS, González González D. Feasibility and efficacy of high dose conformal radiotherapy for patient with locally advanced pancreatic carcinoma. Cancer 2000;89:2222–2229.
   PubMed Web of Science ®Google Scholar
• Whittington R, Neuberg D, Tester WJ, Benson AB 3rd, Haller DG. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a Phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995;13:227–232.
   PubMed Web of Science ®Google Scholar
• Morganti AG, Trodella L, Valentini V, Macchia G, Alfieri S, Smaniotto D, Luzi S, Costamagna G, Doglietto GB, Cellini N. Concomitant gemcitabine (Gemzar) and extended nodes irradiation in the treatment of pancreatic and biliary carcinoma: a phase I study. Onkologie 2003;26(4):325–329.
   PubMed Web of Science ®Google Scholar
• Mattiucci GC, Morganti AG, Valentini V, Ippolito E, Alfieri S, Antinori A, Crucitti A, D'Agostino GR, Di Lullo L, Luzi S, Mantini G, Smaniotto D, Doglietto GB, Cellini N. External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study. Int J Radiat Oncol Biol Phys 2010;76(3):831–838.
   PubMed Web of Science ®Google Scholar
• Morganti AG, Valentini V, Macchia G, Mattiucci GC, Costamagna G, Deodato F, Smaniotto D, Luzi S, Balducci M, Barbi S, Perri V, Trodella L, Cellini N. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: phase I-II dose-escalation study. Int J Radiat Oncol Biol Phys 2004;59(5):1454–1460.
   PubMed Web of Science ®Google Scholar
• Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516–1520.
   PubMed Web of Science ®Google Scholar
• Czito BG, Hong TJ, Cohen DP, Petros WP, Tyler DS, Pappas TN, Yu D, Lee CG, Lockhart AC, Morse MA, Fernando N, Hurwitz HI. A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. Cancer Invest 2006;24(1):9–17.
   PubMed Web of Science ®Google Scholar
• Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, Harrington D, Quirk D, Rathore R, Cruff D, Vakharia J, Vora S, Savarese D, Wanebo H. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001;49:1275–1279.
   PubMed Web of Science ®Google Scholar
• Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A. Preoperative chemotherapy, radiotherapy and surgical resection of locally advanced pancreatic cancer. Arch Surg 2000;135:81–87.
   PubMed Web of Science ®Google Scholar
• Kamthan AG, Morris JC, Dalton J, Mandeli JP, Chesser MR, Leben D, Cooperman A, Bruckner HW. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 1997;15:2920–2927.
   PubMed Web of Science ®Google Scholar
• Martin JL, Harvey HA, Lipton A, Martin R. Combined chemoradiotherapy for unresectable pancreatic cancer. Am J Clin Oncol 1999;22:309–314.
   PubMed Web of Science ®Google Scholar
• Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB 3rd. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000;18:3384–3389.
   PubMed Web of Science ®Google Scholar
• Russell RCG. Palliation of pain and jaundice: an overview. Ann Oncol 1999;10:S165–S169.
   PubMed Web of Science ®Google Scholar
• Morganti AG, Trodella L, Valentini V, Barbi S, Macchia G, Mantini G, Turriziani A, Cellini N. Pain relief with short term irradiation in locally advanced carcinoma of the pancreas. J Palliat Care 2003;19(4):258–262.
   PubMed Web of Science ®Google Scholar
• Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, Welsh J, Mehta M, Larson DA, Janjan NA. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guidelines for the performance of Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2004;60(4):1026–1032.
   PubMed Web of Science ®Google Scholar
• Wulf J, Hädinger U, Oppitz U, Thiele W, Flentje M. Stereotactic boost irradiation for targets in abdomen and pelvis. Radiother Oncol 2004;70:31–36.
   PubMed Web of Science ®Google Scholar
• Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, Flentje M. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncologica 2006;45:838–847.
   PubMed Web of Science ®Google Scholar
• Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67(4):1099–1105.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Matsuo Y, Takayama K, Norihisa Y, Mizowaki T, Mitsumori M, Shibuya K, Yano S, Narita Y, Hiraoka M. Current status of stereotactic radiotherapy for lung cancer. Int J Clin Oncol 2007;12(1):3–7.
   PubMed Web of Science ®Google Scholar
• Wersäll PJ, Blomgren H, Lax I, Kälkner KM, Linder C, Lundell G, Nilsson B, Nilsson S, Näslund I, Pisa P, Svedman C. Extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Radiother Oncol 2005;77:88–95.
   PubMed Web of Science ®Google Scholar
• Mollà M, Escude L, Nouet P, Popowski Y, Hidalgo A, Rouzaud M, Linero D, Miralbell R. Fractionated stereotactic radiotherapy boost for ginecologic tumors: an alternative to brachitherapy? Int J Radiat Oncol Biol Phys 2005;62(1):118–124.
   PubMed Web of Science ®Google Scholar
• Deodato F, Macchia G, Grimaldi L, Ferrandina G, Lorusso D, Salutari V, Cilla S, Valentini V, Cellini N, Piermattei A, Scambia G, Morganti AG. Stereotactic radiotherapy in recurrent gynecological cancer: a case series. Oncol Rep 2009;22(2):415–419.
   PubMed Web of Science ®Google Scholar
• Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;58:1017–1021.
   PubMed Web of Science ®Google Scholar
• Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005;63:320–323.
   PubMed Web of Science ®Google Scholar
• Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005;76: 48–53.
   PubMed Web of Science ®Google Scholar
• Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009;115(3):665–672.
   PubMed Web of Science ®Google Scholar
• Chang ST, Goodman KA, Yang GP, Koong AC. Stereotactic body radiotherapy for unresectable pancreatic cancer. Front Radiat Ther Oncol 2007;40:386–394.
   PubMed Web of Science ®Google Scholar
• Papiez L, Timmerman R, DesRosiers C, Randall M. Extracranial stereotactic radioablation: physical principles. Acta Oncol 2003;42(8):882–894.
   PubMed Web of Science ®Google Scholar
• Sailer SL, Rosenman JG, Symon JR, Cullip TJ, Chaney EL. The tetrad and hexad: maximum beam separation as a starting point for noncoplanar 3D treatment planning: prostate cancer as a test case. Int J Radiat Oncol Biol Phys 1994;30(2):439–446.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–1346.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• Salazar OM, Sandhu T, da Motta NW, Escutia MA, Lanzós-Gonzales E, Mouelle-Sone A, Moscol A, Zaharia M, Zaman S. Fractionated halfbody irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 2001;50:765–775.
   PubMed Web of Science ®Google Scholar
• Sutherland HJ, Walker P, Till JE. The development of a method for determining oncology patients’ emotional distress using linear analogue scales. Cancer Nurs 1988;11(5):303–308.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1985;53:457–481.
   Google Scholar
• Burris HA3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403– 2413.
   PubMed Web of Science ®Google Scholar
• Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001;29:9–18.
   PubMedGoogle Scholar
• Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–2001 FFCD/SFRO study. Ann Oncol 2008;19:1592–1599.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH, Alberts SR and Benson AB III. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol 2008;26(Suppl.15):4506a.
   Google Scholar
• Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010;17(8):2092–2101.
   PubMed Web of Science ®Google Scholar
• el-Rayes BF, Shields AF, Vaitkevicius V, Philip PA. Developments in the systemic therapy of pancreatic cancer. Cancer Invest 2003;21(1):73–86.
   PubMed Web of Science ®Google Scholar